tbuckley/cabot-search huggingface dataset:
Associations between Serum Vitamin D and Genetic Variants in Vitamin D Pathways and Age-Related Macular Degeneration in the European Eye Study
Authors: Gareth J. McKay, Ian S. Young, Ann McGinty, Graham C.G. Bentham, Usha Chakravarthy, Mati Rahu, Johan Seland, Gisele Soubrane, Laura Tomazzoli, Fotis Topouzis, Jesus Vioque, Paulus T.V.M. de Jong, Astrid E. Fletcher
Journal: Ophthalmology (2016)
P3.02b-041 Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib
Authors: Xiaomin Niu, Fatao Liu, Yi Zhou, Zhen Zhou, Yun Liu, Zhiwei Chen, Shun Lu
Journal: Journal of Thoracic Oncology (2017)
Rapid Assessment of Minimal Residual Acute Myeloid Leukemia from Peripheral Blood Using a Microfluidic Chip
Authors: Joshua M. Jackson, James Taylor, Malgorzata Witek, Sally A. Hunsucker, Jennifer Paulsen Waugh, Yuri D. Fedoriw, Thomas C. Shea, Steven A. Soper, Paul M. Armistead
Journal: Blood (2015)
Abstract 11748: Edoxaban versus Warfarin in Patients at Increased Risk of Falling - A Subgroup Analysis of the ENGAGE AF-TIMI 48 Trial
Authors: Jan Steffel, Robert P Giugliano, Eugene Braunwald, Sabina Murphy, Michele Mercuri, Youngsook Choi, Elliott M Antman, Christian T Ruff
Journal: Circulation (2015)

Background: Patients at an increased risk of falling are particularly at risk for undertreatment with oral anticoagulation. The current subgroup analysis assessed the relative efficacy and safety of edoxaban vs. warfarin in patients at increased risk of falling in the ENGAGE AF TIMI 48 study. Methods &amp; Results: Nine-hundred patients (4.3%) included in ENGAGE AF-TIMI 48 were judged to be at increased risk of falling by the investigator at randomization. These patients were older (median 77 years (IQR 72, 82) vs. 72 (64, 77); p &lt;0.001), and had a higher prevalence of co-morbidities including prior stroke/TIA, diabetes and coronary artery disease. Patients at increased risk of falling demonstrated a higher risk for stroke or systemic embolism (2.68%/year vs. 1.77%/year, HR 1.51 (95% CI 1.17-1.96, p=0.002), major bleeding (4.72%/year vs. 2.67%/year, HR 1.74 (95% CI 1.39-2.18), p&lt;0.001) and bone fractures (6.04%/year vs. 2.16%/year, HR 2.80 (95% CI 2.28-3.43), p&lt;0.001). No treatment interaction was observed in patients at increased risk of falling, both for efficacy and safety endpoints, except for no fatal bleeds in patients with vs. without increased fall risk treated with edoxaban compared to warfarin. Due to the higher frequency of events, a larger absolute risk reduction was observed under edoxaban compared to warfarin in patients with vs. without increased risk of falling for intracranial hemorrhage and life threatening bleeding. Conclusions: Patients at increased risk of falling are a high-risk subgroup, with an increased risk for both stroke/SEE as well as for bleeding. These patients demonstrate consistent efficacy and safety with edoxaban as compared to well-managed warfarin. The absolute risk of the most severe bleeding complications was higher in patients at increased risk of falling resulting in an even greater absolute risk reduction in these patients with edoxaban vs. warfarin.
Working Toward Better Tissue Repair Therapies: Exposure of MSC to Hypoxic Conditions In Vitro Increases Levels of the Hepatocyte Growth Factor Receptor c-met, Improves Motility, and Induces Phosphorylation of the Pro-Survival Protein AKT.
Authors: Ivana Rosova, Todd E. Meyerrose, Jan A. Nolta
Journal: Blood (2005)
DETECCIÓN AUTOMATIZADA DE ANGIOECTASIAS EN CÁPSULA ENDOSCÓPICA
Authors: MA Alvarez Gonzalez, R Benitez Iglesias, F Noya Urgell, L Carot Bastard, JM Dedeu Cuscó
Journal: Endoscopy (2016)

El diagnostico mediante cápsula endoscópica requiere del visionado por un endoscopista experto. Este sistema conlleva un retraso diagnóstico, una predisposición a errores por la limitación natural de las capacidades humanas y es caro. Un sistema automatizado fiable puede solucionar estas limitaciones. El software comercializado para ayuda al diagnóstico sólo permite eliminar los fotogramas repetidos o seleccionar los que presentan una mayor probabilidad de lesión. No existe un software comercializado capaz de detectar, identificar y caracterizar las lesiones.
Basophil tryptase mMCP-11 plays a crucial role in IgE-mediated, delayed-onset allergic inflammation in mice
Authors: Misako Iki, Kensei Tanaka, Hayato Deki, Mio Fujimaki, Shingo Sato, Soichiro Yoshikawa, Yoshinori Yamanishi, Hajime Karasuyama
Journal: Blood (2016)
Study quoted had flawed design
Authors: N R Dunn, M Campbell
Journal: BMJ (1995)

who had it postnatally; we could find no references where this has been investigated previously.The authors' analysis of risk factors highlights some common misconceptions: a quarter of all the women with eclampsia were parous, 18% of all the women with eclampsia were parous with no history of pre-eclampsia or eclampsia in previous pregnancies, and teenagers were at three times greater risk than older women.Overall, this paper is a sobering reminder of the vigilance required if we are to reduce further the morbidity and mortality from this relatively common condition.
Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy
Authors: Tom F. Brouwer, Dilek Yilmaz, Robert Lindeboom, Maurits S. Buiten, Louise R.A. Olde Nordkamp, Martin J. Schalij, Arthur A. Wilde, Lieselot van Erven, Reinoud E. Knops
Journal: Journal of the American College of Cardiology (2016)

Transvenous implantable cardioverter-defibrillators (TV-ICDs) improve survival in patients at risk for sudden cardiac death, but complications remain an important drawback. The subcutaneous ICD (S-ICD) was developed to overcome lead-related complications. Comparison of clinical outcomes of both device types in previous studies was hampered by dissimilar patient characteristics. This retrospective study compares long-term clinical outcomes of S-ICD and TV-ICD therapy in a propensity-matched cohort. The authors analyzed 1,160 patients who underwent S-ICD or TV-ICD implantation in 2 high-volume hospitals in the Netherlands. Propensity matching for 16 baseline characteristics, including diagnosis, yielded 140 matched pairs. Clinical outcomes were device-related complications requiring surgical intervention, appropriate and inappropriate ICD therapy, and were reported as 5-year Kaplan-Meier rate estimates. All 16 baseline characteristics were balanced in the matched cohort of 140 patients with S-ICDs and 140 patients with TV-ICDs (median age 41 years [interquartile range: 30 to 52 years] and 40% women). The complication rate was 13.7% in the S-ICD group versus 18.0% in the TV-ICD group (p = 0.80). The infection rate was 4.1% versus 3.6% in the TV-ICD groups (p = 0.36). Lead complications were lower in the S-ICD arm compared with the TV-ICD arm, 0.8% versus 11.5%, respectively (p = 0.03). S-ICD patients had more nonlead-related complications than TV-ICD patients, 9.9% versus 2.2%, respectively (p = 0.047). Appropriate ICD intervention (antitachycardia pacing and shocks) occurred more often in the TV-ICD group (hazard ratio [HR]: 2.42; p = 0.01). The incidence of appropriate (TV-ICD HR: 1.46; p = 0.36) and inappropriate shocks (TV-ICD HR: 0.85; p = 0.64) was similar. The complication rate in patients implanted with an S-ICD or TV-ICD was similar, but their nature differed. The S-ICD reduced lead-related complications significantly, at the cost of nonlead-related complications. Rates of appropriate and inappropriate shocks were similar between the 2 groups.
TCT-522 The Independence of Coronary Microvascular Dysfunction from Epicardial Disease Severity: Three-Vessel Invasive Coronary Physiologic Study
Authors: Yuhei Kobayashi, Joo Myung Lee, William Fearon, None janghoon Lee, Frederik Zimmermann, Ji-Hyun Jung, None hyunjong lee, Joon-Hyung Doh, Chang-Wook Nam, Eun-Seok Shin, Bon-Kwon Koo
Journal: Journal of the American College of Cardiology (2016)
Vitamin B6 and Cancer Risk: A Field Synopsis and Meta-Analysis
Authors: Simone Mocellin, Marta Briarava, Pierluigi Pilati
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Vitamin B6 is involved in many biochemical reactions and might play a role in carcinogenesis. We summarized the evidence linking vitamin B6 to cancer risk. Methods: We conducted a systematic review of both observational and intervention studies investigating the relationship between vitamin B6 intake or blood levels of its bioactive form pyridoxal-5'-phosphate (PLP) and the risk of any type of cancer. Random-effects meta-analysis was used to calculate pooled relative risks (RRs) and their 95% confidence intervals (CIs) across studies for high vs low categories of vitamin intake or PLP levels. We also performed a random-effects dose-response meta-analysis. Results: We identified 121 observational studies (participants, n = 1 924 506; cases, n = 96,436) and nine randomized controlled trials (RCTs; participants, n = 34 911; cases, n = 2539) considering 19 tumor sites. High intake of dietary (food only) vitamin B6 was statistically significantly associated with lower risk of all cancers (relative risk [RR] = 0.78, 95% CI = 0.73 to 0.84) and specific tumors, with special regard to gastrointestinal carcinomas (RR = 0.68, 95% CI = 0.61 to 0.75). An inverse association was also observed between high PLP levels and the risk of all cancers (RR = 0.66, 95% CI = 0.58 to 0.76) and single tumor sites, the most consistent results being those for gastrointestinal tumors (RR = 0.56, 95% CI = 0.48 to 0.65). There was a statistically significant inverse linear relationship between cancer risk and both vitamin B6 dietary intake and PLP levels. When total (food and supplements) intake was considered, the associations were weaker or null. Findings from RCTs did not support a protective effect of vitamin B6 against cancer, although this evidence was graded as low level. Conclusions: Epidemiological evidence supports the potential of vitamin B6 as a cancer risk reduction agent and the role of PLP as a cancer screening biomarker, especially for gastrointestinal tumors. However, inconsistent findings from total intake and intervention studies suggest that vitamin B6 might also be an indicator of other dietary protective micronutrients.
TCT-776 Vascular Healing Response after Implantation of a Novel Fluoropolymer-Coated Paclitaxel-Eluting Peripheral Stent: a Comparative Drug-Eluting Stent Study in a Familial Hypercholesterolemic Swine Model of Balloon-Injured Femoral Arteries
Authors: Pawel Gasior, Yanping Cheng, Andres Valencia, Alex Estrada, Jenn McGregor, Kamal Ramzipoor, Chang Lee, Gerard Conditt, Juan Granada
Journal: Journal of the American College of Cardiology (2016)
ESTUDIO RETROSPECTIVO SOBRE LA UTILIDAD DEL ENDOCUFF VISION EN LA DETECCIÓN DE PÓLIPOS EN EL CRIBADO DE CÁNCER COLORRECTAL EN LAS ÁREAS 2 Y 3 DE LA PROVINCIA DE CASTELLÓN
Authors: F Sábado, J Pitarch, A Bolós, B Castelló, V Martinez, MP Silva, JA Peris
Journal: Endoscopy (2016)

Introducción: El cribado de cáncer colorrectal (CCCR) se realiza para detectar lesiones premalignas y extirparlas. Endocuff Vision es un dispositivo cuya utilidad es ayudar a detectar pólipos en zonas de peor acceso y/o visualización.
The Ski oncoprotein regulates Hematopoietic Stem Cell Fitness and Functions as a Corepressor for Gfi1.
Authors: Chinavenmeni S. Velu, Michael Berk, Haiming Xu, Tristan Bourdeau, Avedis Kazanjian, David A. Williams, Clemencia Colmenares, H. Leighton Grimes
Journal: Blood (2008)
The effect of prior abiraterone (Abi) treatment on subsequent response to docetaxel in men with castrate resistant prostate cancer (CRPC).
Authors: Michael Thomas Schweizer, Xian Chong Zhou, Hao Wang, Sunakshi Bassi, Michael Anthony Carducci, Mario A. Eisenberger, Emmanuel S. Antonarakis
Journal: Journal of Clinical Oncology (2014)

136 Background: Taxanes are hypothesized to mediate their effect in CRPC, at least in part, by disrupting androgen receptor trafficking along microtubules. This raises the possibility of cross-resistance between androgen-directed agents (e.g., Abi) and Tax. Methods: We retrospectively evaluated Tax efficacy in CRPC patients (N=119) who did (Abi+Tax; n=24) or did not (Tax; n=95) receive prior Abi. To ensure a contemporaneous control group, this analysis only included men who started Tax between 12/2007 (the date we began using Abi at our center) and 5/2013. Univariate and propensity score-weighted multivariable analyses for PSA progression-free survival (PSA-PFS) and all-cause progression-free survival (PFS) were conducted to evaluate the effect of prior Abi on responses to Tax. Results: Men in the Abi+Tax group had a significantly higher risk of progression than those in the Tax group. In univariate analysis, PSA-PFS was shorter in the Abi+Tax group (HR 2.00; 95%CI 1.13–3.52; P=0.016), as was PFS (HR 1.97; 95%CI 1.13–3.41; P=0.016). Median PSA-PFS was 4.1 mo in the Abi+Tax group and 6.3 mo in the Tax group (P=0.014). Median PFS was also shorter in the Abi+Tax group (4.1 vs 6.8 mo; P=0.014). In multivariable analysis, prior Abi treatment remained a predictor of shorter PSA-PFS and PFS (Table). PSA declines ≥50% were also less frequent in the Abi+Tax group (37% vs 63%, P=0.04). Conclusions: Men receiving Abi prior to Tax were more likely to develop progression on Tax (and less likely to have a PSA response) than Abi-naive patients. Cross-resistance between Abi and Tax may limit taxane efficacy in Abi-pretreated patients. [Table: see text]
The Cardiovascular Risk of White-Coat Hypertension
Authors: Stanley S. Franklin, Lutgarde Thijs, Kei Asayama, Yan Li, Tine W. Hansen, José Boggia, Lotte Jacobs, Zhenyu Zhang, Masahiro Kikuya, Kristina Björklund-Bodegård, Takayoshi Ohkubo, Wen-Yi Yang, Jørgen Jeppesen, Eamon Dolan, Tatiana Kuznetsova, Katarzyna Stolarz-Skrzypek, Valérie Tikhonoff, Sofia Malyutina, Edoardo Casiglia, Yuri Nikitin, Lars Lind, Edgardo Sandoya, Kalina Kawecka-Jaszcz, Jan Filipovský, Yutaka Imai, Ji-Guang Wang, Eoin O’Brien, Jan A. Staessen
Journal: Journal of the American College of Cardiology (2016)
Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)
Authors: Maro Ohanian, Hagop M. Kantarjian, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Elias Jabbour, Marina Konopleva, Miranda Lim, Sherry Pierce, Susan O'Brien, Bradley G. Somer, Ana Tari, William Wierda, Srdan Verstovsek, Jorge E. Cortes
Journal: Blood (2015)
A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.
Authors: Amrita Y. Krishnan, Auayporn Nademanee, Andrew Raubitschek, Henry C. Fung, Arturo Molina, David Yamauchi, Peter M. Falk, Ricardo Spielberger, Joycelynne Palmer, Ni Chun Tsai, Jeffrey Schriber, Stephen J. Forman
Journal: Blood (2006)
TCT-170 Clinical Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From DUTCH PEERS (TWENTE II) Randomized Trial
Authors: K. Gert van Houwelingen, Liefke van der Heijden, Ming Kai Lam, Marije Lowik, Peter Danse, R. Melvyn Tjon Joe Gin, Gillian A. Jessurun, Rutger L. Anthonio, Hanim Sen, Gerard C.M. Linssen, Maarten J. IJzerman, Carine J.M. Doggen, Clemens von Birgelen
Journal: Journal of the American College of Cardiology (2016)
TCT-108 Comparison of Ticagrelor versus Prasugrel on Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients with Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting: Prospective, Randomized, Cross-Over Design
Authors: Eulogio García, Soonjun Hong, Sang-A. Cho, Jae Young Cho, Seung Hun Lee, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Do Sun Lim
Journal: Journal of the American College of Cardiology (2016)
Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility
Authors: Zhimiao Lin, Shuo Li, Cheng Feng, Shang Yang, Huijun Wang, Danhui Ma, Jing Zhang, Mengting Gou, Dingfang Bu, Tengjiang Zhang, Xiaohui Kong, Xintong Wang, Ofer Sarig, Yali Ren, Lanlan Dai, Hankui Liu, Jianguo Zhang, Fei Li, Yongyan Hu, Gilly Padalon-Brauch, Dan Vodo, Feng Zhou, Ting Chen, Haiteng Deng, Eli Sprecher, Yong Yang, Xu Tan
Journal: Nature Genetics (2016)
Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression in patients with NAFLD
Authors: Serena Pelusi, Salvatore Petta, Chiara Rosso, Vittorio Borroni, Anna Ludovica Fracanzani, Paola Dongiovanni, Antonio Craxi, Elisabetta Bugianesi, Silvia Fargion, Luca Valenti
Journal: Hepatology (2016)
Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group
Authors: Lidia Usnarska-Zubkiewicz, Jakub Debski, Aleksandra K. Butrym, Wojciech Legiec, Marek Hus, Anna Dmoszynska, Beata Stella-Holowiecka, Jan M Zaucha, Marcin Rymko, Tigran Torosian, Grzegorz Charlinski, Ewa Lech-Maranda, Artur J. Jurczyszyn, Halina Urbanska-Rys, Agnieszka Druzd-Sitek, Kazimierz Kuliczkowski
Journal: Blood (2013)
P1.13 (also presented as PD2.01): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar
Authors: Luis E. Raez, Edgardo S. Santos, Jennifer Mourafetis, Alice Y. Kim, Brian Hunis, Candice Sareli, Lilibeth Castillero, Evelio Velis
Journal: Journal of Thoracic Oncology (2016)
Capecitabine combined with Irinotecan (CapIri) as first line treatment of advanced colorectal carcinoma (ACRC): A phase ll study
Authors: J. Zidan, W. Basher, J. Shnaider, S. Tmam, A. Abzah, L. Chetver
Journal: Journal of Clinical Oncology (2006)

13569 Background: The combination of 5-FU + LV with irinotecan as first line treatment of advanced colorectal cancer (ACRC) has shown higher response rate compared with 5-FU +LV with the same progression free survival. Capecitabine is more active than 5-FU.The aim of this study is to determine the side-effect profile, dose limiting toxicity and response rate to CapIri combination as first line treatment in ACRC, on an outpatient basis. Methods: Inclusion criteria: age &gt;18–75 years, ECOG ≤ (0–3), measurable disease, no previous treatment for advanced disease, previous adjuvant chemo-therapy more than 6 months is allowed, signed informed consent and adequate hepatic, renal and hematological function. Exclusion criteria: Serious concurrent medical disorders, prior other malignancy, pregnancy or breast-feeding and patients with poor compliance. Capecitabine 1000mg/m 2 twice daily was given for 14 days followed by 7 days rest and Irinotecan (100mg/m 2 ) was given days 1 and 8. Treatment was repeated on day 2. Results: 28 patients (pts) were included. All patients were assessable for response and toxicity. Average age was 64 years, male/female ratio 20/8. Fourteen pts had liver metastases, 5 had lung and 9 had abdominal metastases. Median No of cycles was 4. Grade III and IV diarrhea was observed in 12 (44%) pts, vomiting in 9 (31%) pts, fatigue in 12 (44%) pts, grade IV leucopenia in 5 (17%) pts. Complete response was achieved in 3 (11%) pts, partial response in 15 (53%), stabilization of disease in 5 (18%) and tumor progression in 5 (18%) pts. Progression free survival is 8.4 months. Overall survival is not yet available. Conclusions: This regimen appears feasible with acceptable toxicity except for grade III diarrhea, on an outpatient treatment basis, with significant antitumor activity, without the requirement for indwelling catheters. It is also feasible for older patients. No significant financial relationships to disclose.
LA ASCITIS DETECTADA POR USE PREDICE LA EXISTENCIA DE CARCINOMATOSIS PERITONEAL EN LOS PACIENTES CON ADENOCARCINOMA DE PÁNCREAS
Authors: C Sánchez-Montes, C Tuñón, N Alberghina, J Ferrer, J Maurel, JR Ayuso, IK Araujo, O Sendino, À Ginès, G Fernández-Esparrach
Journal: Endoscopy (2016)

Introducción: la carcinomatosis peritoneal (CP) impacta en el manejo de los pacientes con adenocarcinoma de páncreas pero su diagnóstico puede ser difícil.
Excellent Engraftment and Long-Term Survival in Patients with Severe Aplastic Anemia (SAA) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Haplo-Identical CD34+ Cells Combined with a Single Umbilical Cord Blood Unit
Authors: Enkhtsetseg Purev, Georg Aue, Ritesh Kotecha, Jennifer Wilder, Hahn M. Khuu, David F. Stroncek, Roger Kurlander, Robert N. Reger, Willy A. Flegel, Sharon Adams, Lisa Cook, Catalina Ramos, Elena Cho, Richard W. Childs
Journal: Blood (2015)
TCT-447 The Promus Premier everolimus-eluting platinum chromium Stent with durable polymer Evaluated in a real world All-comer population in Rotterdam Cardiology Hospital (the P-SEARCH registry)
Authors: Miguel Lemmert, Nicolas Van Mieghem, Robert-Jan van Geuns, Roberto Diletti, Ron Vandomburg, Evelyn Regar, Felix Zijlstra, Eric Boersma, Joost Daemen
Journal: Journal of the American College of Cardiology (2016)
A single-center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients (pts) with advanced cancer
Authors: S. Nallapareddy, D. Gustafson, S. Leong, W. Messersmith, J. Arnott, S. G. Eckhardt, C. Sidor, D. R. Camidge
Journal: Journal of Clinical Oncology (2009)

3562 Background: ENMD-1198 (2-methoxyestra-1, 3, 5, (10) 16-tetraene-3-carboxamide), an analog of 2-methoxyestradiol (2ME2), has both antiangiogenic and antiproliferative effects in various tumor types. ENMD-1198 inhibits MT polymerization by binding to β-tubulin at the colchicine-binding site and inhibits HIF-1alpha. This Phase 1 study is evaluating the safety of ENMD-1198 to determine the maximum tolerated dose. Methods: Eligible pts had advanced cancer for which no effective therapy exists that is either evaluable by RECIST criteria or tumor markers that could be monitored for clinical benefit. Phase 1 dose escalation in 3+3 design for first 5 cohorts; modified to 1 pt cohorts for subsequent cohorts until Grade 2 treatment related toxicity, and then standard 3+3 design. All pts treated with once daily oral ENMD-1198 in 28-day cycles (with post-treatment drug-free observation period of 7–14 days in Cycle 1 only). Pts are treated until the appearance of significant treatment-emergent toxicities or disease progression (PD) occurs. Results: To date, 27 pts have been enrolled in 12 dose cohorts (range 5 to 550 mg/m 2 /d). Median age/performance status is 61/1. Total # of treatment cycles to date is 68, with a median of 2 cycles (range &lt;1 to 15 cycles). Most frequent toxicities (all grades, n=22) were pain (77%), fatigue (55%), constipation (36%), neuropathy and nausea (both 32%), and anemia (27%). 4 pts have experienced stable disease (SD) for more than 2 cycles. There have been no objective responses to date. 2 pts experienced dose limiting toxicity with Grade 4 neutropenia in the 550 mg/m 2 /d cohort. Following drug holiday, pts restarted at 425 mg/m 2 /d and continued for at least 1–2 more cycles before being removed from study for PD. One pt (neuroendocrine ca pancreas) is experiencing prolonged SD at 60 mg/m 2 /d &gt;14 cycles and a 2nd pt (prostate ca) experienced SD at 30mg/m 2 /d for 10 cycles. ENMD-1198 was absorbed rapidly after oral administration. There was a linear relationship between dose and drug exposure as measured by AUC across all doses (5 - 550 mg/m 2 ). The elimination half-life of ENMD- 1198 averaged more than 12 hours after a single dose. Conclusions: DLT was identified at 550 mg/m 2 /d. Cohort expansion at 425mg/m 2 /d is ongoing. [Table: see text]
TCT-709 Trans-apical Transcatheter Aortic Valve Replacement in Patients with History of Coronary Artery Bypass Grafting: An Analysis from the National Inpatient Sample Database
Authors: S. Chiu Wong, Konstantinos Voudris, Geoffrey Bergman, Robert Minutello, Richard Devereux, Rajesh Swaminathan, Harsimran Singh, Dmitriy Feldman, Luke Kim, Arash Salemi
Journal: Journal of the American College of Cardiology (2016)